target directory

cd19 clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT07549698

Source recordAI-normalized

A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

CRISPR Therapeutics AG is advancing CTX112, an allogeneic CAR T-cell therapy targeting CD19, for the treatment of relapsed/refractory hematologic autoimmune diseases, specifically Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA). The market for therapies addressing these conditions is significant, given the limitations of existing treatments and the unmet need for effective options. CTX112's allogeneic nature and CRISPR-Cas9 engineering may provide a competitive edge in terms of off-the-shelf availability and rapid deployment compared to autologous therapies. The trial's success could position CRISPR Therapeutics favorably in the CAR T-cell therapy landscape, particularly as interest in gene editing technologies continues to grow.

AI analysis

Indication: Warm Autoimmune Hemolytic Anemia (WAIHA)

Modality: gene therapy

Target: CD19

Sponsor: CRISPR Therapeutics AG

Source URL: ClinicalTrials.gov

Source updated: Jun 15, 2026

Ingested: Jun 19, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: CD19

View original source fields

Condition raw: Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura

Condition normalized: Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura

Modality raw: gene therapy

Modality normalized: gene therapy

Target raw: CD19

Target normalized: CD19

Open report

NCT04184414

Source recordAI-normalized

CD19-CART Cells in the Treatment of CD19+ r/r B Cell-derived Hematological Malignancies

PersonGen BioTherapeutics is developing CD19-CART cells targeting CD19+ B-cell malignancies, particularly in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and other hematological malignancies. The market for CAR T-cell therapies is expanding, with significant competition from established players like Novartis and Gilead. The unique focus on CD19, a well-characterized target in B-cell cancers, positions PersonGen favorably, but the company must navigate regulatory pathways and demonstrate robust clinical efficacy to secure market share. The potential for Ig supplementation in long-term therapy may also influence treatment adoption and reimbursement strategies.

AI analysis

Indication: B Acute Lymphoblastic Leukemia

Modality: small molecule

Target: CD19

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Source URL: ClinicalTrials.gov

Source updated: Dec 03, 2019

Ingested: Jun 18, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: CD19

View original source fields

Condition raw: B Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma

Condition normalized: B Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma

Modality raw: small molecule

Modality normalized: small molecule

Target raw: CD19

Target normalized: CD19

Open report